AJENAT PHARMS
Big PharmaAJENAT PHARMS is a major pharmaceutical company focused on Infectious Disease, Dermatology, Neurology.
AJENAT PHARMS's Key Drugs
AJENAT PHARMS's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).
AJENAT PHARMS's Recent FDA Approvals
New NDA/BLA approvals for AJENAT PHARMS over the last two years — novel drugs only, excluding generics and label supplements.
AJENAT PHARMS's Therapeutic Areas
AJENAT PHARMS's approved drugs and pipeline span 5 therapeutic areas, led by Infectious Disease and Dermatology. Weighted by commercial stage — approved drugs count most, then late-stage trials.
AJENAT PHARMS's Top Competitors
AJENAT PHARMS's closest competitors by therapeutic-area and drug-target overlap include Pfizer, Bristol-Myers Squibb, and PAI HOLDINGS PHARM. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
AJENAT PHARMS Pipeline Snapshot
Active clinical trials for AJENAT PHARMS across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • Top drug revenue breakdown
- • Drug-level revenue analysis
Trial Catalysts
- • Infectious Disease pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (0)
Discontinued (0)
Company Info
- First Approval
- 1943-12-31
- Latest
- 2025-10-27
- Applications
- 17